Role of alpha5 nicotinic acetylcholine receptors in pharmacological and behavioral effects of nicotine in mice.
Incorporation of the alpha5 nicotinic acetylcholine receptor (nAChR) subunit can greatly influence nAChR function without altering receptor number. Although few animal studies have assessed the role of the alpha5 nAChR in nicotine-mediated behaviors, recent evidence suggests an association between polymorphisms in the alpha5 nAChR gene and nicotine dependence phenotypes in humans. Thus, additional studies are imperative to elucidate the role and function of the alpha5 nAChR subunit in nicotine dependence. Using alpha5(-/-) mice, the current study aimed to examine the role of alpha5 nAChRs in the initial pharmacological effects of nicotine, nicotine reward using the conditioned place preference model, and the discriminative effects of nicotine using a two-lever drug discrimination model. (86)Rb(+) efflux and (125)I-epibatidine binding assays were conducted to examine the effect of alpha5 nAChR subunit deletion on expression and activity of functional nAChRs. Results show that alpha5(-/-) mice are less sensitive to the initial effects of nicotine in antinociception, locomotor activity, and hypothermia measures and that the alpha5 nAChR is involved in nicotine reward. Alternatively, alpha5(-/-) mice did not differ from wild-type littermates in sensitivity to the discriminative stimulus effects of nicotine. Furthermore, deletion of the alpha5 nAChR subunit resulted in a statistically significant decrease in function in the thalamus and hindbrain, but the decreases noted in spinal cord were not statistically significant. Receptor number was unaltered in all areas tested. Taken together, results of the study suggest that alpha5 nAChRs are involved in nicotine-mediated behaviors relevant to development of nicotine dependence.
Jackson
K J
KJ
Department of Psychiatry, Pharmacology/Toxicology, Virginia Commonwealth University, Richmond, VA 23298-0613, USA. jacksonkj@vcu.edu
Marks
M J
MJ
Vann
R E
RE
Chen
X
X
Gamage
T F
TF
Warner
J A
JA
Damaj
M I
MI
D000701:Analgesics, Opioid / Q000494:pharmacology; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D001831:Body Temperature; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D007035:Hypothermia / Q000139:chemically induced / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009020:Morphine / Q000494:pharmacology; D009043:Motor Activity / Q000187:drug effects; D009538:Nicotine / Q000494:pharmacology*; D018722:Nicotinic Agonists / Q000494:pharmacology; D010146:Pain / Q000378:metabolism; D017288:Pain Threshold / Q000187:drug effects; D011485:Protein Binding; D011978:Receptors, Nicotinic / Q000235:genetics / Q000502:physiology*; D013116:Spinal Cord / Q000187:drug effects / Q000378:metabolism; D013574:Synaptosomes / Q000187:drug effects / Q000378:metabolism
D000701:Analgesics, Opioid; D009020:Morphine; D009538:Nicotine; D018722:Nicotinic Agonists; D011978:Receptors, Nicotinic; C523972:CHRNA5 protein, mouse
J Neurosci. 1999 Nov 1;19(21):9298-305
10531434
J Neurochem. 2008 Jan;104(2):446-56
17961152
J Pharmacol Exp Ther. 1998 Jul;286(1):311-20
9655874
Curr Drug Targets CNS Neurol Disord. 2002 Aug;1(4):331-6
12769607
J Neurosci. 2002 Oct 15;22(20):8785-9
12388584
J Neurosci. 2000 Sep 1;20(17):6431-41
10964949
J Neurochem. 2000 Jul;75(1):18-27
10854242
Nature. 1998 Jan 8;391(6663):173-7
9428762
Physiol Genomics. 2004 Apr 13;17(2):221-9
14996991
J Pharmacol Exp Ther. 1999 Oct;291(1):390-8
10490929
J Biol Chem. 1996 Jul 26;271(30):17656-65
8663494
J Pharmacol Exp Ther. 2007 Jul;322(1):399-407
17446302
J Pharmacol Exp Ther. 1998 Apr;285(1):377-86
9536034
J Mol Neurosci. 2010 Jan;40(1-2):91-5
19693710
Mol Pharmacol. 2004 Jun;65(6):1526-35
15155845
J Neurochem. 2007 Oct;103(1):204-15
17573823
J Pharmacol Exp Ther. 2007 Jun;321(3):1161-9
17371806
J Pharmacol Exp Ther. 2008 Apr;325(1):302-12
18184829
J Pharmacol Exp Ther. 1999 May;289(2):1090-103
10215692
Mol Psychiatry. 2008 Apr;13(4):368-73
18227835
PLoS Genet. 2008 Jul 11;4(7):e1000125
18618000
Nature. 1996 Mar 28;380(6572):347-51
8598930
Brain Res. 1990 Aug 27;526(1):45-53
2078817
Biochem Pharmacol. 2007 Oct 15;74(8):1102-11
17597586
J Neurosci. 2009 Mar 11;29(10):3014-8
19279237
Hum Mol Genet. 2007 Jan 1;16(1):36-49
17135278
Nature. 1999 Apr 29;398(6730):805-10
10235262
Science. 2004 Nov 5;306(5698):1029-32
15528443
Psychopharmacology (Berl). 2006 Mar;184(3-4):339-44
16416156
Neuropharmacology. 2002 Mar;42(4):530-9
11955523
Mol Pharmacol. 2002 Mar;61(3):695-705
11854451
Psychopharmacology (Berl). 2007 Feb;190(2):157-70
17115136
J Pharmacol Exp Ther. 1998 Mar;284(3):1058-65
9495867
Neuropharmacology. 2007 Sep;53(3):390-405
17631923
J Neurosci. 1992 Jul;12(7):2765-84
1613557
Mol Pharmacol. 2007 Mar;71(3):769-76
17132685
Nature. 2008 Apr 3;452(7187):638-642
18385739
Am J Psychiatry. 2008 Sep;165(9):1163-71
18519524
Mol Pharmacol. 2003 May;63(5):1059-66
12695534